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Summary
Hepatitis C virus (HCV) is a global health problem and
a leading cause of liver disease. Here, we demonstrate
that the replication of HCV replicon RNA in Huh-7 cells
is inhibited by a peroxisome proliferator-activated
receptor (PPAR) antagonist, 2-chloro-5-nitro-N-(pyridyl)
benzamide (BA). Downregulation of PPARg with RNA
interference approaches had no effect on HCV replica-
tion in Huh-7 cells, whereas PPARadownregulation in-
hibited HCV replication. Fluorescence and coherent
anti-Stokes Raman scattering (CARS) microscopy
demonstrate a clear buildup of lipids upon treatment
with BA. These observations are consistent with the
misregulation of lipid metabolism, phospholipid secre-
tion, cholesterol catabolism, and triglyceride clear-
ance events associated with the inhibition of PPARa.
The inhibition of HCV replication by BA may result
from disrupting lipidation of host proteins associated
with the HCV replication complex or, more generally,
by disrupting the membranous web where HCV repli-
cates.
Introduction
Hepatitis C virus (HCV) infection is a rapidly increasing
global health problem, with approximately 3% of the
global population infected. It is responsible for 40%–
60% of chronic liver disease worldwide [1]. Clinical effi-
cacy of modern therapeutics is limited, and no vaccines
are currently available [2–8]. Central to HCV’s life cycle
are host-virus interactions that support infection, repli-
cation, and viral particle assembly on a molecular level.
HCV is a positive strand RNA virus of the family Flavivir-
idae and has anw9.6 kb genome that is translated into
a large polyprotein. Thisw3,000 amino acid polyprotein
[1] is cleaved into at least 10 mature viral proteins. They
include the core protein and envelope proteins (C, E1,
and E2), which are the structural proteins of the virus;
*Correspondence: john.pezacki@nrc-cnrc.gc.caa small hydrophobic protein of unknown function (p7);
and the rest of the proteins indicated as nonstructural
proteins (NS2–NS5B) [1]. HCV can induce changes in
host cell structure and function. For example, HCV is
known to induce changes in lipid metabolism [9, 10],
and it induces the formation of ER-derived membra-
nous webs on which HCV replicates [11, 12]. HCV also
induces steatosis, the accumulation of lipid droplets
on which HCV structural proteins are known to reside
[13–16]. HCV replication requires localization of HCV
NS5B and the associated complexing proteins to mem-
branous structures of the host cell [17, 18]. Peroxisome
proliferator-activated receptors (PPARs) play an im-
portant role in controlling gene expression of lipid me-
tabolism [19]. Therefore, PPAR-mediated alterations in
lipid homeostasis are likely to have an influence on HCV
replication.
Peroxisomes are organelles bound by a single mem-
brane and are involved in various metabolic functions
(fatty acid oxidation, peroxide-derived respiration, cho-
lesterol catabolism, for example) within the cell. PPARs
are the nuclear receptors responsible for the effects of
ligands, collectively known as peroxisome proliferators,
that alter both the number and size of peroxisomes [19].
First cloned from mouse liver in 1990, PPARs are ligand-
dependant transcription factors that share common
structural features, including a highly conserved central
DNA binding domain, C-terminal ligand binding domain,
and a variable N-terminal domain. There are three iden-
tified PPAR isoforms in mammals: a, b/d, and g [20–26].
These isoforms are encoded by separate genes and dif-
fer in their localization, function, and ligand specificity.
PPARa is primarily expressed in tissues with high lipid
metabolism, including brown adipose tissue and liver,
as well as the kidney, heart, and skeletal muscle [20–
22]. PPARb/d has the highest expression in the gut, kid-
ney, and heart, although it is expressed to a lesser extent
in many other tissues [20]. PPARg is primarily expressed
in adipose tissue, and it is also expressed in the colon,
immune system, and the retina [20].
PPAR receptors represent important pharmaceutical
targets for the treatment of diseases, including diabetes,
that involve the misregulation of glucose, cholesterol,
and fatty acid metabolism [27]. PPAR receptors natu-
rally bind to a number of fatty acids and metabolites
as well as synthetic ligands [28–30]. Glitazones, includ-
ing thiazolidinediones (TZD) and fibrates, are classes
of drugs that activate PPAR receptors and show either
glucose- and/or lipid-lowering effects [28–30]. Rosiglita-
zone and pioglitazone are two examples of TZD drugs
that are effective in lowering glucose levels by targeting
PPARg and also have a modest effect on lipid levels
through crossreactivity with other isoforms [31, 32]. It
is common that agonists or antagonists of PPAR activity
show crossreactivity between isoforms. Farglitazar has
robust effects on glucose, high-density lipoproteins,
and triglycerides in diabetic patients [27]. Crossreactiv-
ity of ligands between PPARa and PPARg is most com-
mon primarily because the ligand binding pockets are
closest in size and shape to each other [29, 30]. Also,
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Figure 1. The Activity of Benzamide BA against Subgenomic HCV Replicons in Huh-7 Cells
(A) Schematic representation of the subgenomic replicons used in this study (see Experimental Procedures).
(B) Luciferase reporter gene activity (relative light units; RLU) of Huh7 cells stably expressing an HCV subgenomic replicon derived from
pFK-I389neo/luc/NS3-30/5.1. Note that our RLUs are divided by 1000 for ease in presentation. Activity was determined after 24 hr of exposure
to increasing concentrations of 2-chloro-5-nitro-N-(pyridyl)benzamide. Data have been normalized against total protein content. M, 1% v/v
MeOH; U, untreated replicon bearing Huh-7 cells. The IC50 of BA is expressed as a percentage of the maximal response after 24 hr of exposure
to benzamide.
(C) Expression of HCV NS3 protein. Lanes are: H, Huh-7 cells; U, untreated Huh-7 cells stably harboring an HCV subgenomic replicon de-
rived from pFK-I389/neo/NS3-30/5.1; M, 1% v/v MeOH; 25OH, 2 mM 25-hydroxycholesterol; LS, 50 mM lovastatin; BA, 2-chloro-5-nitro-N-
(pyridyl)benzamide (25, 50, 75 mM); IFNg, 50 U interferon g.
Data have been normalized against total protein content. Error bars were determined from statistical treatment of triplicate measurements.a major determinant of this selectivity is thought to be
due to a substitution of Tyr-314 in PPARa for His-323
in PPARg [29, 30]. The antagonist 2-chloro-5-nitro-N-
(pyridyl)benzamide inhibits PPARg activity by covalently
modifying cysteine 313 [23]. This antagonist also shows
crossreactivity toward other isoforms [23]. Thus, antag-
onists of PPARg/a that do not discriminate between iso-
forms on a molecular level can affect both lipid metabo-
lism and glucose homeostasis.
The liver is the central organ involved in fat metabolism
and lipid homeostasis [28]. It is involved in free fatty acid
synthesis, esterification of triacylglycerols, and their
packaging into very low-density lipoproteins (VLDL) for
exportation during the fed state [28]. During the fasted
state, the liver is responsible for controlling the rates of
fatty acid b-oxidation and ketogenesis. The liver main-
tains lipid homeostasis by balancing these processes.
A key mediator in maintaining this balance is PPARa
[22, 24–26]. PPARa acts as a sensor for the level of free
fatty acids and modulates the responses of fat-oxidizing
tissues [28]. Activation of PPARa results in an increase in
the enzymes involved in lipid metabolism and fatty acid
b-oxidation. These enzymes include apolipoproteins,
fatty acid binding proteins, medium chain acyl-CoA dehy-
drogenase, carnitine palmitoyl-transferase, and micro-
somal fatty acid u-hydroxylase [25, 28]. PPARa knock-
out mice develop fatty livers and respond very poorly
to fasting, resulting in hepatic lipid accumulation, hypo-
glycemia, and impaired ketogenesis [24, 28, 33, 34].
PPARa has also been shown to be impaired during
HCV infections [35, 36], implying a role for PPARa in
HCV infection and pathogenesis. Here, we show, by us-
ing Huh-7 cells harboring subgenomic HCV replicons,
that PPARaantagonism results in a decrease in HCV viral
replication. The decrease in viral replication is linked withan observed misregulation of lipid homeostasis that in-
creases the intracellular lipid content.
Results
The Effects of PPARa/g Antagonist
2-Chloro-5-Nitro-N-(Pyridyl)Benzamide
on HCV Replication
In order to test the importance of PPAR activity, we first
examined the effects of 2-chloro-5-nitro-N-(pyridyl)
benzamide, BA [23], which targets PPARg, and to a
lesser extent, PPARa. Throughout this study, we used
subgenomic HCV replicons [12, 37, 38], which are a
well-established cellular model for HCV replication, in
order to study host-virus molecular interactions that re-
sult from perturbation of PPAR signaling. In particular,
we utilized Huh-7 cells harboring a tricistronic subge-
nomic HCV replicon, constructed from HCV genomic
RNA of the genotype 1b, derived from the clone pFK-
I389neo/luc/NS3-30/5.1, which was previously charac-
terized [9, 39] (schematically represented in Figure 1A),
and we evaluated BA activity by utilizing the genetic re-
porter luciferase. After 24 hr of exposure, BA concentra-
tion dependence of the luciferase signal was observed
(Figure 1B). We utilized 1% v/v methanol in complete
media as the negative control or mock treatment as
well as 25-hydroxycholesterol, lovastatin, and interferon
g as positive controls [9, 10, 40]. We found that higher
concentrations of the benzamide were as effective at re-
ducing HCV replicon levels as interferon treatments. Cy-
totoxicity assays after 24 hr treatments indicated that
this compound was detrimental to cell viability only at
concentrations at or above 100 mM. Furthermore, treated
cells recovered from these effects after 72 hr, suggest-
ing that the altered metabolic condition of the treated
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25cells may result from the misregulation of genes tran-
scriptionally regulated by PPARa. An IC50 against the
HCV replicon for 2-chloro-5-nitro-N-(pyridyl)benzamide
was determined to be 19.1 mM (Figure 1C), consistent
with the IC50 of this ligand for the PPARa isoform [23],
which is w800-fold lower than that for PPARg. Higher
concentrations of BA that are needed to reduce HCV
replication are likely the result of PPAR isoform-specific
effects on the HCV replication complex. Independent
confirmation of the decrease in replication rate was ob-
tained by performing Western blot analysis of cell ly-
sates for the HCV NS3 protein (Figure 1D). We examined
loading by using control antibodies against tubulin and
the protein-tyrosine phosphatase PTP1D. PTP1D was
found to be a better control for Western blots, as it was
determined that BA binds to tubulin at high concentra-
tions (ca. 100 mM). The effects of BA on PPARa signaling
and lipid metabolism were confirmed by quantitative
PCR analysis of mitochondrial HMG-CoA synthase
mRNA levels by using the 18S rRNA levels as a control.
Treatment of Huh-7 cells bearing HCV replicons with BA
for 24 hr resulted in decreases in HMG-CoA synthase
levels from 5- to <60-fold for BA concentrations ranging
between 20 mM and 75 mM (see Supplemental Data avail-
able with this article online).
The Effects of siRNA Molecules and Mammalian
Gene Overexpression on HCV Replication
In order to determine the molecular basis for the anti-
HCV activity of 2-chloro-5-nitro-N-(pyridyl)benzamide,
we examined the role of direct gene knockdown by uti-
lizing standard RNA interference techniques. Utilizing
the tricistronic HCV replicon (illustrated in Figure 1A),
we tested the effects of siRNAs that target PPARa and
PPARg. Oligonucleotide duplexes that target luciferase
GL2 and GL3 were used as positive and negative con-
trols, respectively. The luciferase GL2 oligonucleotides
specifically target the firefly luciferase gene contained
within the tricistronic HCV replicon, whereas GL3 targets
a different luciferase isoform. All of the siRNAs were
tested according to manufacturer’s protocols to ensure
target knockdown (see the experiment described be-
low). Downregulation of the target gene was confirmed
by Western blot, although the PPARa protein levels
upon treatment with siRNA were onlyw50% lower than
those of mock-transfected cells (see Supplemental
Data). We found that knockdown of PPARa mRNA had
an effect on HCV replication but that this was not as sig-
nificant a decrease as was observed for the benzamide
ligand (Figure 2). Knockdown of PPARg with siRNA had
no effect on HCV replication. Examination of PPARg
mRNA levels in gene expression data (unpublished
data) suggests that this isoform is probably not consti-
tutively expressed in Huh-7 cells. Overexpression of
PPARa with a CMV promoter also had little effect on
HCV replication, as did typical PPARa agonists such as
WY-14643 ([4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio]
acetic acid). Overexpression with the CMV promoter
was confirmed to be at least 2-fold higher than controls
by Western blot (see Supplemental Data).
Next, we studied the effect of BA in the context of
overexpression of PPARa using the overexpression vec-
tor pCMV-PPARa (see Experimental Procedures). We
compared the effects of BA on HCV replicons in mock-transfected cells and in cells transiently transfected
with the overexpression vector. PPARa expression
was confirmed by Western blot. We observed that the
BA compound was less effective at inhibiting HCV repli-
cation in cells overexpressing PPARa, confirming the
specificity of BA for PPARa in the Huh-7 and HCV repli-
con cell lines. These observations provide further sup-
port that inhibition of HCV replication by BA results
from antagonism of the PPARa protein.
The Effects of PPARg/a Antagonist
2-Chloro-5-Nitro-N-(Pyridyl)Benzamide
on Lipid Content in Huh-7 Cells
In order to determine the morphological effects of treat-
ing cells with the PPAR antagonist 2-chloro-5-nitro-N-
(pyridyl)benzamide, we first examined cells by confocal
fluorescence microscopy. Huh-7 cells were treated with
various concentrations of BA for various lengths of time.
These cells were then fixed and stained for lipids with oil
red O dye and were counterstained with DAPI (Figure 3).
We see a noticeable increase in lipid droplet accumula-
tion in the presence of BA, and this is consistent with the
observations made previously regarding the link be-
tween the PPARa receptor and lipid accumulation in
clinical HCV infections [35, 36].
We used coherent anti-Stokes Raman scattering
(CARS) microscopy to examine the effects of BA on liv-
ing Huh-7 cells. CARS microscopy is a powerful imaging
modality that is derived from the inherent vibrations
of molecules. CARS microscopy can image samples
with molecular specificity, without the need for labeling,
by tuning the frequency difference between the two
laser beams into a specific molecular vibration. CARS
offers the ability to image live cells [41, 42] and tissues
[43] with high spatial resolution in real time. In this
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Figure 2. Luciferase Reporter Gene Activity Represented by Nor-
malized Relative Light Units of Huh-7 Cells Stably Expressing an HCV
Subgenomic Replicon Derived from pFK-I389neo/luc/NS3-30/5.1
Activity was determined after 72 hr treatments: M-siRNA, mock
siRNA treatment; GL2, siRNA molecule targeting the luciferase
gene; GL3, siRNA control molecule; M-siRNA-V, control for vectors
expressing scrambled siRNA; PPARa and PPARg, siRNA vectors
targeting PPARa and PPARg; pCMV-PPARa, overexpression vec-
tor for PPARa; M-EtOH, 1% v/v ethanol; 25-HC, 2 mM 25-hydroxy-
cholesterol; IFNg, 50, 100, and 500 U treatments with interferon g.
Data have been normalized against total protein content. Data have
been normalized against total protein content. Error bars were de-
termined from statistical treatment of triplicate measurements.
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26Figure 3. Fluorescence Microscopy of Oil Red O and 40,6-Diamidino-2-Phenylindole (DAPI)-Stained Huh-7 Cells Stably Expressing an HCV
Subgenomic Replicon Derived from pFK-I389neo/NS3-30/5.1
(A–D) Cells were imaged after 24 hr under the following conditions: (A) untreated; (B) 1% v/v MeOH; (C) 25 mM BA; (D) 50 mM BA.experiment, the CARS system was tuned to the strong
lipid CH2 vibrational resonance at 2845 cm
21 in order
to selectively image lipids.
We performed a time course examination of Huh-7
cells upon treatment with the PPAR antagonist BA by
using CARS microscopy tuned to illuminate lipids (Fig-
ure 4). A clear increase in cellular lipids after treatment
with BA was observed. The effects on these live cells
were clearly more dramatic and not limited to lipid drop-
let accumulation (Figure 4A). An increase in lipid content
in Huh-7 cells treated with BA was observed compared
to untreated and mock-treated cells that were also im-aged in CARS microscopy experiments for the duration
of the time course. The observed increase in lipid con-
tent within the Huh-7 cells can be attributed to de-
creases in fatty acid activation, transport, b-oxidation,
secretion, triglyceride clearance, and cholesterol catab-
olism, which is consistent with what is known about
PPARa signaling in the liver [21, 25, 28, 44].
Immunostaining for the HCV polymerase gene NS5B
in the replicon-bearing Huh-7 cells was conducted in
the presence of BA. Treatments were conducted for
6 hr at concentrations ranging from 0 to 75 mM (Fig-
ures 4B–4F). These experiments were conducted toFigure 4. CARS and Fluorescence Microscopy of the Effects BA Elicits in Lipid Homeostasis
(A) Huh-7 cells were incubated at 37ºC and 5% CO2 after treatment with 50 mM BA. The CARS microscope was tuned to the lipid stretch at
2845 cm21, and images were acquired at 60 min intervals over 6 hr.
(B–F) Fluorescent microscopy of NS5B (green) immunostained Huh-7 cells bearing subgenomic HCV replicons, counterstained with oil red O
(red) and DAPI (blue). (A) Huh-7 cells bearing HCV subgenomic replicons that were (B) 1% v/v MeOH treated and (C–E) treated with 25, 50, and
75 mM BA for 6 hr.
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27determine if mediation of PPAR signaling affected levels
and subcellular localization of the HCV protein NS5B.
Consistent with previous studies [18, 45–47], we ob-
serve NS5B subcellular localization concentrating in
the perinuclear region where membranous web struc-
tures are known to reside. We observe a decrease in sig-
nal intensity for NS5B with increasing doses of BA that
is consistent with the NS3 Western blot data (Figure
1D). The benzamide also appears to enhance cellular
permeability of the antibodies at lower doses. Fluores-
cence microscopy shows no evidence for an alteration
of NS5B subcellular localization, although it is possible
that NS5B and the associated replication complexes
are dispersed upon treatment with BA.
Discussion
The PPARa nuclear hormone receptor plays a critical
role in regulating liver-specific metabolic functions
through obligate heterodimerization with RXR and LXR
and subsequent transactivation of genes containing
PPREs in their promoter regions [24, 25, 44, 48, 49]. Mis-
regulation of this gene or its downstream targets has
also been implicated in liver-specific disease states.
PPARa activation over prolonged periods is linked to tu-
morigenesis in rats [49], the development of steatosis,
and delayed liver regeneration in knockout mice after
partial hepatectomy [48, 50–52]. Hepatocellular levels
of PPARa and carnitine palmitoyl acyl-CoA transferase
1 (CPT1A) have been shown to be depressed in un-
treated patients with HCV infections [35, 36]. A link be-
tween this disruption of PPARa gene expression at the
mRNA level and HCV core protein expression in
HepG2 cells, and thus a link between PPARa and HCV
pathogenesis, has also been made [36]. Here, we show
that perturbation of PPARa with either an antagonist or
siRNA also has a negative effect on HCV replication. Us-
ing a genetic reporter for HCV RNA levels, and by West-
ern blot analyses, we have characterized the anti-HCV
effects of BA and siRNA’s targeting of the PPARa gene
(Figures 1 and 2). Each of the latter acted to inhibit
HCV replication in HCV replicons with different rates
and reactivities. The PPARa/g antagonist BA acted
more rapidly and with a higher efficacy.
We have observed that time required for siRNAs to
significantly affect luciferase reporter levels is much lon-
ger (48–72 hr) than that observed with BA (6–24 hr), sug-
gesting that the disruption of HCV replication occurs
more rapidly with the PPARa small-molecule antagonist.
This is likely owing to the rapidity by which the small
molecule can diffuse to its target, and to the fact that it
can act directly on the receptor posttranslationally
[23]. Antagonists of PPARa are known to downregulate
HMG-CoA synthase transcriptionally, which we con-
firmed by quantitative PCR. Antagonists of PPARa
also induce hyperlipidemia, in contrast with the action
of agonists [24, 26, 44]. This phenotype was confirmed
by using fluorescence and CARS microscopy. More-
over, CARS microscopy allowed for a more detailed ex-
amination of the kinetics of BA action in live cells
through indirect observations of the hyperlipidimic con-
dition resulting from its action on PPARa. We observed
an increase in lipid content within 1–2 hr after treatment
of Huh-7 cells with BA (Figure 4). These results are con-sistent with a loss of HCV replicon replication as mea-
sured by HCV NS3 (Figure 1D) and NS5B (Figures 4C–
4F) levels.
There are a number of possible mechanisms by which
2-chloro-5-nitro-N-(pyridyl)benzamide inhibits HCV rep-
lication in the replicon model. While it is possible that
this small molecule may interact directly with HCV pro-
teins involved in replication, siRNA experiments (Fig-
ure 2) suggest that the mechanism likely involves the
downstream effects of PPARa antagonism. Hyperlipid-
emia can also disrupt replication complexes by altering
membranous structures in which replication occurs [11,
12], or by altering the lipidation of host proteins that are
necessary for replication to occur [10, 53]. Previous
studies have indicated that genes associated with lipid
metabolism, such as SCAP- and SREBP-regulated
genes of the mevalonate pathway, are differentially reg-
ulated during the initial stages of HCV infection and that
these genes may be predictors of the outcome of vire-
mia [9]. Lovastatin, a potent inhibitor of HMG-CoA re-
ductase that catalyzes the conversion of HMG-CoA to
mevalonic acid (the rate-limiting step in the synthesis
of cholesterol) [54], and GGTI-286, an inhibitor of a gera-
nylgeranyl transferase enzyme, also inhibit HCV replica-
tion by an indirect route [10, 53]. Transcriptional regula-
tion of hepatocellular genes, including lipid transfer
genes such as HMG-CoA synthase and CPT1A, by
PPARa is well-documented [20–22, 27–29]. We suggest
that the most likely mechanism of anti-HCV action of the
benzamide involves posttranslational antagonism of
PPARa, and that this subsequently alters the transcrip-
tional regulation of a number of gene products including
those that regulate lipid metabolism and lipid transfer.
The effects are likely enhanced relative to the siRNA ow-
ing to crossreactivity of the small-molecule antagonist.
Significance
We have demonstrated that both small molecules and
siRNA molecules that perturb the function of PPARa
also inhibit HCV replication in replicon systems. This
activity is linked with a hyperlipidemic condition within
the Huh-7 cells, although it is not necessarily causally
related. There exists strong evidence that chronic HCV
infections are associated with the impaired expression
of PPARa, and the likely culprit leading to this change
in the host cell is the core protein of HCV [35, 36]. Our
data suggest that the impaired expression of PPARa
during chronic infection is not advantageous to HCV
propagation. Rather, a consequence of chronic infec-
tion may favor the host rather than the virus in control-
ling the levels of HCV in the infected liver. This may
also be a mechanism by which HCV controls its own
levels in vivo in an evolutionary attempt to evade the
host immune response. Further experiments that ex-
amine the precise mechanism by which PPARa in-
hibits the HCV lifecycle may aid in the identification
of novel targets for therapeutic intervention.
Experimental Procedures
Tissue Culture
Cell monolayers of the human hepatoma cell line Huh-7 were grown
in DMEM medium supplemented with 100 nM nonessential amino
acids, 50 U/ml penicillin, 50 mg/ml streptomycin, and 10% FBS
Chemistry & Biology
28(CANSERA, Rexdale, ON). HCV replicons were maintained in the
same medium plus 250 mg/ml G418 Geneticin (GIBCO-BRL, Burling-
ton, Ontario). Huh-7 cells stably replicating HCV replicons derived
from the pFK-I389neo/NS3-30/5.1 subgenomic replicon were kindly
provided by Ralf Bartenschlager (Institute of Hygiene, University of
Heidelberg, Heidelberg, Germany), and the pFK-I389neo/luc/NS3-
30/5.1 plasmid is described elsewhere [9, 39].
Small-Molecule Treatments
Huh-7 cells harboring the HCV subgenomic replicon were seeded at
1 3 104 cells/well in DMEM in a 96-well plate. After 24 hr, at a con-
fluency of 70%–80%, cells were treated with BA (1–500 mM), for
24 hr. The effect of the benzamide molecule on Huh-7 cells was an-
alyzed by luciferase and toxicity assays. The same conditions were
followed for treatments with 25-hydroxycholesterol (2.5 mM), lova-
statin (50 mM), and interferon g (50–500 U/ml).
Overexpression and siRNA Transfection in HCV Replicon Cells
The siRNA duplexes homologous to GL2 and GL3 luciferases were
purchased from Dharmacon (Lafayette, CO). The siRNA vector
mixes, targeting the PPARa and/or the PPARg gene, were pur-
chased from Panomics (Redwood City, CA). The siRNA or overex-
pression vector transfections were routinely done in 96-well plates
according to the manufacturer’s protocol, and assays were carried
out at 48, 72, and 96 hr posttransfection.
Luciferase Reporter Assay and Protein Quantification
Huh-7 cells harboring subgenomic replicons were transfected with
siRNA or treated with the benzamide compound as described previ-
ously. At assay endpoints, cells were washed once with PBS and
lysed with cell culture lysis buffer (Promega, Madison, WI). Lucifer-
ase assay substrate was added, and the relative light units (RLU)
were measured with an Lmax luminometer (Molecular Devices Cor-
poration, Sunnyvale, CA). Values were normalized against total pro-
tein content by doing the Bio-Rad DC Protein Assay (Bio-Rad, Mis-
sissauga, ON) according to the manufacturer’s protocol.
Immunoblot Analysis
Huh-7 cells harboring subgenomic replicons (1 3 106 cells) were
seeded in 60 mm dishes for preparation of Western blot lysates. Af-
ter small-molecule treatment, cells were washed and lysed with an
SDS lysis buffer consisting of 50 mM Tris-HCl (pH 6.8), 2% SDS,
10% glycerol, 100 mM dithiothreitol (DTT), and 0.1% bromophenol
blue (prepared without the DTT and bromophenol blue). A protease
inhibitor cocktail mix (Roche Diagnostics, Penzberg, Germany) was
added to each extract. The protein concentration of each sample
was quantified by using the Bio-Rad DC Protein Assay according
to the manufacturer’s protocol. Prior to loading, 10% v/v of DTT
and bromophenol blue (1:1) were added to each sample, and
60 mg/well was loaded onto a SDS-PAGE gel (10% resolving, 4%
stacking gel). The resolved proteins were transferred to a Hybond-P
(Amersham Biosciences, Piscataway, NJ) polyvinylidene difluoride
membrane. The membrane was probed against HCV NS3 protein
by using a mouse anti-NS3 1º antibody (1:500 dilution, ViroStat, Port-
land, ME) followed by a 2º (HRP)-conjugated goat anti-mouse IgG
antibody (1:1000 dilution) obtained from Jackson ImmunoResearch
Laboratories, Inc. (Westgrove, PA). As a loading control, a mouse
PTP1D 1º antibody (1:2500 dilution; Sigma, Saint Louis, MO) was
used with the same 2º antibody described above. Protein bands
were visualized by Western Lightning Western Blot Chemilumines-
cence reagents (PerkinElmer Life and Analytical Sciences, Inc., Bos-
ton, MA) according to the manufacturer’s protocol.
Cytotoxicity Assays
Huh-7 cells expressing the HCV subgenomic replicon were treated
as described above. After 24 hr, cells were washed and lysed with
Triton X-100, and a CytoTox 96 Non-Radioactive Cytotoxicity Assay
(Promega, Madison, WI) was performed according to the manufac-
turer’s protocol. The absorbance was read with a Spectramax M2
(Molecular Devices Corporation, Sunnyvale, CA), by using SOFTmax
Pro software, at 490/650 nm.Immunofluorescence Analysis
The fluorescent imaging of Huh-7 cells harboring the subgenomic
replicon was performed by using an Axiovert 200M inverted micro-
scope from Zeiss (North York, ON) with the Axiovision 3.1 software.
The cells were photographed with an AxioCam connected to the in-
verted microscope. Cells were probed for HCV NS5B protein and in-
cubated with mouse anti-NS5B (5B-12B7) 1º antibody (1:100 dilution
kindly provided by Darius Moradpour, Department of Medicine II,
University of Freiburg, Freiburg, Germany), followed by incubation
with Cy2-labeled donkey anti-mouse IgG 2º antibody (1:100 dilution,
Jackson ImmunoResearch Laboratories, Inc., Westgrove, PA). Cells
were stained for lipids with oil red O (0.5% in isopropanol; Sigma-
Aldrich, Oakville, ON) and were counterstained with 300 nM DAPI
(Molecular Probes, Eugene, OR).
CARS Imaging of Live Cells
Huh-7 cells were seeded at 53 104 cells/well in 4.2 cm2 borosilicate
culture vessels (VWR, Mont-Royal, PQ) and incubated at 37ºC and
5% CO2. At 70%–80% confluency, the cells were washed once
with prewarmed DMEM, and BA, previously dissolved in methanol
at a concentration of 10 mM, was diluted to 100 mM in DMEM and
added to the cells. CARS signals from the cells were collected in
the forward direction. Typical pump (711 nm) and Stokes (892 nm)
excitation powers were 9 and 3 mW, respectively, at the sample.
A detailed discussion of CARS instrumentation is presented else-
where [41, 42].
Supplemental Data
Supplemental Data including Western blots and functional data for
the validation of isoform-specific activity of BA as well as protocols
and a list of primers used for quantitative PCR analyses can be found
at http://www.chembiol.com/cgi/content/full/13/1/23/DC1/.
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